253 related articles for article (PubMed ID: 33945534)
1. Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes.
Wang S; Li H; Song M; Tao Z; Wu T; He Z; Zhao X; Wu K; Liu XS
PLoS Genet; 2021 May; 17(5):e1009557. PubMed ID: 33945534
[TBL] [Abstract][Full Text] [Related]
2. Sigflow: an automated and comprehensive pipeline for cancer genome mutational signature analysis.
Wang S; Tao Z; Wu T; Liu XS
Bioinformatics; 2021 Jul; 37(11):1590-1592. PubMed ID: 33270873
[TBL] [Abstract][Full Text] [Related]
3. The repertoire of copy number alteration signatures in human cancer.
Tao Z; Wang S; Wu C; Wu T; Zhao X; Ning W; Wang G; Wang J; Chen J; Diao K; Chen F; Liu XS
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36806386
[TBL] [Abstract][Full Text] [Related]
4. Signatures of copy number alterations in human cancer.
Steele CD; Abbasi A; Islam SMA; Bowes AL; Khandekar A; Haase K; Hames-Fathi S; Ajayi D; Verfaillie A; Dhami P; McLatchie A; Lechner M; Light N; Shlien A; Malkin D; Feber A; Proszek P; Lesluyes T; Mertens F; Flanagan AM; Tarabichi M; Van Loo P; Alexandrov LB; Pillay N
Nature; 2022 Jun; 606(7916):984-991. PubMed ID: 35705804
[TBL] [Abstract][Full Text] [Related]
5. Copy number alteration signatures as biomarkers in cancer: a review.
Giles Doran C; Pennington SR
Biomark Med; 2022 Apr; 16(5):371-386. PubMed ID: 35195030
[TBL] [Abstract][Full Text] [Related]
6. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
[TBL] [Abstract][Full Text] [Related]
7. Distinct patterns of complex rearrangements and a mutational signature of microhomeology are frequently observed in PLP1 copy number gain structural variants.
Bahrambeigi V; Song X; Sperle K; Beck CR; Hijazi H; Grochowski CM; Gu S; Seeman P; Woodward KJ; Carvalho CMB; Hobson GM; Lupski JR
Genome Med; 2019 Dec; 11(1):80. PubMed ID: 31818324
[TBL] [Abstract][Full Text] [Related]
8. In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer.
Cava C; Bertoli G; Colaprico A; Bontempi G; Mauri G; Castiglioni I
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562723
[TBL] [Abstract][Full Text] [Related]
9. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
[TBL] [Abstract][Full Text] [Related]
10. An overview of mutational and copy number signatures in human cancer.
Steele CD; Pillay N; Alexandrov LB
J Pathol; 2022 Jul; 257(4):454-465. PubMed ID: 35420163
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.
Greene SB; Dago AE; Leitz LJ; Wang Y; Lee J; Werner SL; Gendreau S; Patel P; Jia S; Zhang L; Tucker EK; Malchiodi M; Graf RP; Dittamore R; Marrinucci D; Landers M
PLoS One; 2016; 11(11):e0165089. PubMed ID: 27851748
[TBL] [Abstract][Full Text] [Related]
12. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
13. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
14. Spatially resolved clonal copy number alterations in benign and malignant tissue.
Erickson A; He M; Berglund E; Marklund M; Mirzazadeh R; Schultz N; Kvastad L; Andersson A; Bergenstråhle L; Bergenstråhle J; Larsson L; Alonso Galicia L; Shamikh A; Basmaci E; Díaz De Ståhl T; Rajakumar T; Doultsinos D; Thrane K; Ji AL; Khavari PA; Tarish F; Tanoglidi A; Maaskola J; Colling R; Mirtti T; Hamdy FC; Woodcock DJ; Helleday T; Mills IG; Lamb AD; Lundeberg J
Nature; 2022 Aug; 608(7922):360-367. PubMed ID: 35948708
[TBL] [Abstract][Full Text] [Related]
15. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
Xia S; Kohli M; Du M; Dittmar RL; Lee A; Nandy D; Yuan T; Guo Y; Wang Y; Tschannen MR; Worthey E; Jacob H; See W; Kilari D; Wang X; Hovey RL; Huang CC; Wang L
Oncotarget; 2015 Jun; 6(18):16411-21. PubMed ID: 25915538
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Genomic Profiling of Androgen-Receptor-Negative Canine Prostate Cancer.
Laufer-Amorim R; Fonseca-Alves CE; Villacis RAR; Linde SAD; Carvalho M; Larsen SJ; Marchi FA; Rogatto SR
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925701
[TBL] [Abstract][Full Text] [Related]
18. MutVis: Automated framework for analysis and visualization of mutational signatures in pathogenic bacterial strains.
Prasanna A; Niranjan V
Infect Genet Evol; 2021 Jul; 91():104805. PubMed ID: 33689914
[TBL] [Abstract][Full Text] [Related]
19. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
[TBL] [Abstract][Full Text] [Related]
20. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
